Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M

SOLENO THERAPEUTICS INC

2025-Q3 EPS reported -$0.45 revenue$98,675,000

Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.
1,043 patient start forms and 764 active patients on VYKAT XR as of Sept 30, 2025; 494 unique prescribers and over 132M lives covered since March approval.
Cash and securities at $556.1M, including $230M gross proceeds from July common stock offering; operating cash flow of $43.5M in Q3.
Sequential product revenue more than doubled from $32.7M in Q2 2025; R&D expense fell to $8.4M from $30.1M, and SG&A to $33.8M from $49.2M.
Appointed Mark W. Hahn to Board of Directors and Audit Committee; contingent consideration liability for Essentialis earnout estimated at $19.5M.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.